{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:58:34Z","timestamp":1790747914731,"version":"4.1.0"},"reference-count":51,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Science Progress"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Hidradenitis suppurativa (HS) is a painful inflammatory skin disease within the pilosebaceous unit associated with numerous comorbidities, including obesity type-2-diabetes (T2DM), and a general meta-inflammatory state. This narrative review explores the therapeutic potential of GLP-1-receptor-agonists (GLP-1RAs) in treating HS by analyzing mechanisms of action and clinical outcomes. Based on a literature search, encompassing 12 cohorts and 4 case-based reports, current evidence demonstrates significant improvements in both clinical and patient-reported outcomes in patients with HS treated with GLP-1RAs. Treatment consistently resulted in reduced body mass index (BMI) and disease activity, measured by Hurley-staging and the number of nodules and abscesses. Patients across studies experienced fewer flares and less pain, supporting improvements in dermatology quality of life (DLQI) scores. Studies observed reductions in systemic inflammatory markers and improved glycemic control. The beneficial effects of GLP-1RAs in HS are attributed to the reduction in mechanical friction and metabolic improvements from weight loss. Suggestively, concurrent and direct anti-inflammatory mechanisms, including inhibition of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\u03baB) signaling pathway and modulation of cytokines, occur independently of weight-reduction. Results from cohorts and cases supported this theory, showing significant improvements in HS and metabolic markers independent of weight-related outcomes. Four supplementary cohorts found GLP-1RAs beneficial for cardiovascular comorbidities in patients with HS. Additionally, studies suggest that GLP-1RAs enhance the efficacy of biologic therapies used for HS and reduce the need for adjunctive treatment. In conclusion, GLP-1RAs represent a promising pleiotropic treatment within a multimodal therapy strategy for HS and comorbidities.<\/jats:p>","DOI":"10.1177\/00368504261464855","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T08:55:42Z","timestamp":1782982542000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical and mechanistic effects of GLP-1 receptor agonists in hidradenitis suppurativa and comorbidities"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3752-4114","authenticated-orcid":false,"given":"Emma","family":"Brogaard","sequence":"first","affiliation":[{"name":"Copenhagen University Hospital - Bispebjerg and Frederiksberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valdemar Wendelboe","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital - Bispebjerg and Frederiksberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja H\u00f8jgaard","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital - Bispebjerg and Frederiksberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaj","family":"Holgersen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital - Bispebjerg and Frederiksberg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4838-300X","authenticated-orcid":false,"given":"Simon Francis","family":"Thomsen","sequence":"additional","affiliation":[{"name":"Copenhagen University Hospital - Bispebjerg and Frederiksberg"},{"name":"University of Copenhagen"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"e_1_3_7_2_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098428"},{"key":"e_1_3_7_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.2373"},{"key":"e_1_3_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14511"},{"key":"e_1_3_7_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13671-024-00446-8"},{"key":"e_1_3_7_6_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24076596"},{"key":"e_1_3_7_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19556"},{"issue":"4","key":"e_1_3_7_8_2","first-page":"422","article-title":"Exploring the Therapeutic Potential of GLP-1 Agonists in Hidradenitis Suppurativa","volume":"24","author":"Parvathaneni A","year":"2025","unstructured":"Parvathaneni A, McQuitty EN, Slawin B, et al. Exploring the Therapeutic Potential of GLP-1 Agonists in Hidradenitis Suppurativa. J Drugs Dermatol 2025; 24(4): 422\u2013423. https:\/\/doi.org\/10.36849\/JDD8725","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"e_1_3_7_9_2","first-page":"260","article-title":"T helper 17 cell\/regulatory T-cell imbalance in hidradenitis suppurativa\/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities","volume":"179","author":"Melnik BC","year":"2018","unstructured":"Melnik BC, John SM, Chen W, et al. T helper 17 cell\/regulatory T-cell imbalance in hidradenitis suppurativa\/acne inversa: the link to hair follicle dissection, obesity, smoking and autoimmune comorbidities. Br J Dermatol 2018; 179(2): 260\u2013272. https:\/\/doi.org\/10.1111\/bjd.16561","journal-title":"Br J Dermatol"},{"issue":"5","key":"e_1_3_7_10_2","first-page":"885","article-title":"Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel","volume":"240","author":"Offidani A","year":"2024","unstructured":"Offidani A, Marzano AV, Peris K, et al. Guidelines How to Integrate Surgery and Targeted Therapy with Biologics for the Treatment of Hidradenitis Suppurativa: Delphi Consensus Statements from an Italian Expert Panel. Dermatology 2024; 240(5-6): 885\u2013896. https:\/\/doi.org\/10.1159\/000539264","journal-title":"Dermatology"},{"key":"e_1_3_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20472"},{"key":"e_1_3_7_12_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475419874412"},{"key":"e_1_3_7_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/ced\/llad182"},{"issue":"9","key":"e_1_3_7_14_2","first-page":"93282","article-title":"Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review","volume":"17","author":"Tassavor B","year":"2025","unstructured":"Tassavor B, Al Salem S. Use of Glucagon-Like Peptide-1 (GLP-1) Agonists in Modulating Preexisting Dermatologic Disease: A Systematic Review. Cureus 2025; 17(9): 93282. https:\/\/doi.org\/10.7759\/cureus.93282","journal-title":"Cureus"},{"key":"e_1_3_7_15_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13216292"},{"key":"e_1_3_7_16_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41073-019-0064-8"},{"key":"e_1_3_7_17_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14599"},{"key":"e_1_3_7_18_2","doi-asserted-by":"publisher","DOI":"10.1159\/000517017"},{"key":"e_1_3_7_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2025.01.021"},{"key":"e_1_3_7_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells13010065"},{"issue":"4","key":"e_1_3_7_21_2","first-page":"745","article-title":"Tirzepatide \u2014 a dual GIP\/GLP-1 receptor agonist \u2014 a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes","volume":"73","author":"Nowak M","year":"2022","unstructured":"Nowak M, Nowak W, Grzeszczak W. Tirzepatide \u2014 a dual GIP\/GLP-1 receptor agonist \u2014 a new antidiabetic drug with potential metabolic activity in the treatment of type 2 diabetes. Endokrynol Pol 2022; 73(4): 745\u2013755. https:\/\/doi.org\/10.5603\/EP.a2022.0029","journal-title":"Endokrynol Pol"},{"issue":"5","key":"e_1_3_7_22_2","article-title":"Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes","volume":"16","author":"Mikhail N","year":"2023","unstructured":"Mikhail N. Retatrutide as a Novel Treatment for Obesity and Type 2 Diabetes. Curr Res Diabetes Obes J 2023; 16(5). https:\/\/doi.org\/10.19080\/CRDOJ.2023.16.555949","journal-title":"Curr Res Diabetes Obes J"},{"key":"e_1_3_7_23_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17091115"},{"key":"e_1_3_7_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/20420188231222367"},{"key":"e_1_3_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-025-01537-5"},{"key":"e_1_3_7_26_2","doi-asserted-by":"publisher","DOI":"10.36849\/jdd.7325"},{"key":"e_1_3_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2025.07.003"},{"key":"e_1_3_7_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2025.103936"},{"key":"e_1_3_7_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.06.463"},{"key":"e_1_3_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.356"},{"key":"e_1_3_7_31_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2025.2723"},{"key":"e_1_3_7_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2023.11.007"},{"issue":"1","key":"e_1_3_7_33_2","first-page":"476","article-title":"Are we treating more than weight Effects of liraglutide 3mg for the treatment of obesity among patients with hidradenitis suppurativa","volume":"17","author":"Nicolau J","year":"2024","unstructured":"Nicolau J, Nadal A, Tamayo M, et al. Are we treating more than weight Effects of liraglutide 3mg for the treatment of obesity among patients with hidradenitis suppurativa. Obesity Facts 2024; 17(Supplement 1): 476. https:\/\/doi.org\/10.1159\/000538577","journal-title":"Obesity Facts"},{"key":"e_1_3_7_34_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20392"},{"key":"e_1_3_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2024.02.023"},{"key":"e_1_3_7_36_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15233"},{"key":"e_1_3_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2023.07.359"},{"key":"e_1_3_7_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae216"},{"key":"e_1_3_7_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000473873"},{"key":"e_1_3_7_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/12034754251320045"},{"key":"e_1_3_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.1277"},{"key":"e_1_3_7_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljaf085.149"},{"key":"e_1_3_7_43_2","first-page":"e140","article-title":"GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study","volume":"40","author":"Chou PP","year":"2025","unstructured":"Chou PP, Jeong C, Ma E, et al. GLP-1RAs and cardiovascular risk reduction in hidradenitis suppurativa: A real-world cohort study. J Eur Acad Dermatol Venereol 2025; 40: e140\u2013e142. https:\/\/doi.org\/10.1111\/jdv.20874","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"e_1_3_7_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.17910"},{"issue":"8","key":"e_1_3_7_45_2","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jid.2025.06.1335","article-title":"LB1062 The impact of GLP-1 receptor agonists on major adverse cardiovascular events among hidradenitis suppurativa, psoriasis, and atopic dermatitis patients: A population-based cohort study","volume":"145","author":"Ma EJ","year":"2025","unstructured":"Ma EJ, Roberts A, Jeong C, et al. LB1062 The impact of GLP-1 receptor agonists on major adverse cardiovascular events among hidradenitis suppurativa, psoriasis, and atopic dermatitis patients: A population-based cohort study. J Invest Dermatol 2025; 145(8 Supplement): 185, Society for Investigative Dermatology (SID) 2025. Hilton San Diego Bayfront, San Diego United States. https:\/\/doi.org\/10.1016\/j.jid.2025.06.1335","journal-title":"J Invest Dermatol"},{"key":"e_1_3_7_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(25)00996-9"},{"key":"e_1_3_7_47_2","doi-asserted-by":"publisher","DOI":"10.1159\/000504843"},{"key":"e_1_3_7_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.16565"},{"key":"e_1_3_7_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2025.05.329"},{"key":"e_1_3_7_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2024.11.039"},{"key":"e_1_3_7_51_2","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13050127"},{"key":"e_1_3_7_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20369"}],"container-title":["Science Progress"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261464855","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/00368504261464855","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/00368504261464855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:19:55Z","timestamp":1790745595000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/00368504261464855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1177\/00368504261464855"],"URL":"https:\/\/doi.org\/10.1177\/00368504261464855","relation":{},"ISSN":["0036-8504","2047-7163"],"issn-type":[{"value":"0036-8504","type":"print"},{"value":"2047-7163","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"article-number":"00368504261464855"}}